SAFETY DATA SHEETS

This SDS packet was issued with item:

078073252

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078480827



MATERIAL SAFETY DATA SHEET

SECTION 1 - PRODUCT & COMPANY IDENTIFICATION

1501 East Woodfield Road

Emergency Telephone

(800) 551-7176

Suite 300 East

Schaumburg, IL 60173

(847) 969-2700

Product Identifier: Levothyroxine Sodium for Injection

Chemical Name: Levothyroxine Sodium

Category: Hormone

SECTION 2 - COMPOSITION

<u>Ingredient</u> <u>CAS Number</u> <u>Amount</u>

Levothyroxine Sodium 55-03-8 200 mcg and 500

mcg per vial

Mannitol 69-65-8 10 mg per vial

Tribasic Sodium Phosphate Anhydrous 7601-54-9 0.7 mg per vial

SECTION 3 - HAZARDS IDENTIFICATION

Route of Entry: Inhalation, eye/skin contact, or ingestion

Chemical Listing as

Carcinogen

NTP: No

IARC: No

OSHA: No

Note: NA

SECTION 4 - EMERGENCY & FIRST AID MEASURES

Eyes: Immediately flush eyes with water for at least 15 minutes. Seek medical attention.

Skin: Remove contaminated clothing immediately. Flush area with water for at least 15

minutes. Wash exposed area with soap and water. Seek medical attention if pain,

redness, or swelling persists.

Levothyroxine Sodium for Injection Revision date: 03/02/07, Version: 2.0.0 Abraxis BioScience, Inc.

Page 1 of 5

SECTION 4 - EMERGENCY & FIRST AID MEASURES... continued

Inhalation: Move exposed subject to fresh air immediately. Give artificial respiration and

cardiopulmonary resuscitation (CPR) if required. Seek medical attention.

Ingestion: Flush mouth out with water immediately. Seek medical attention.

Contact Info: For Adverse Event Information, please call (800) 551-7176 or (847) 969-2700.

SECTION 5 - FIRE FIGHTING MEASURES

Fire and Explosion Data

Closed Cup Flash

200.0

Point:

Open Cup Flash

NE

Point:

Fire Point:

NE

Autoignition:

NE

Lower Explosion

NE

Limit:

Upper Explosion

NE

Limit:

2.....

When heated to decomposition, toxic fumes may be emitted.

Fire Fighting

Instructions:

General Hazard:

instructions

Use water or a type ABC multi-purpose extinguisher.

Fire Fighting

Equipment:

Wear self-containing breathing apparatus and protective clothing.

Hazardous Combustion

Products:

May emit noxious fumes of iodine, iodine compounds, and nitrogen oxides. As with any burning material, carbon monoxide and carbon dioxide may be produced.

SECTION 6 - ACCIDENTAL RELEASE MEASURES

Clean-Up: Wear recommended personal protective equipment (See Section 8 - Exposure

Controls/Personal Protection). Use absorbent towels or brooms to clean-up spill.

Wipe surface area clean with soap and water.

SECTION 7 - HANDLING AND STORAGE

General Handling: When handling pharmaceutical products, avoid all contact and inhalation of dust,

fumes, mist, and/or vapors associated with the product.

Levothyroxine Sodium for Injection Revision date: 03/02/07, Version: 2.0.0

SECTION 7 - HANDLING AND STORAGE ... continued

Storage Conditions: Store dry product at 20° to 25°C (68° to 77°F) [see USP Controlled Room

Temperature]. Protect from light.

SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION

Engineering Controls: General room ventilation is usually satisfactory. Use local exhaust ventilation if

necessary.

Personal Protective

Equipment

Eye Protection: Safety glasses or goggles recommended.

Hand Protection: Disposable latex gloves recommended.

Respiratory Protection:

With satisfactory ventilation, respiratory protection is usually not required.

Skin Protection: Disposable garments if direct skin contact is anticipated.

Exposure Limits:

Compound Issuer <u>OEL</u> <u>Type</u> Levothyroxine Sodium OSHA PEL NE ACGIH TLV NE Other Limits 0.002 mg/m³

Mannitol OSHA PEL NE **ACGIH** TLV NE

STEL NE Tribasic Sodium Phosphate NE **OSHA** PEL

Anhydrous **ACGIH** TLV NE **STEL** NE

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES

White, lyophilized powder Physical Form/

Appearance:

Boiling Point/Boiling NA

Range:

NE Melting Point/Melting

Range:

NA **Freezing Point:** NA Vapor Pressure:

Relative Vapor Density: NA

NA Percent Volatiles:

Levothyroxine Sodium for Injection Revision date: 03/02/07, Version: 2.0.0

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES... continued

pH:

NE

Molecular Weight:

798.86

Solvent Solubility:

Slightly soluble in water

Note:

NA

SECTION 10 - STABILITY AND REACTIVITY

Stability:

Stable

Conditions to Avoid:

Avoid storage with strong oxidizers. Exposure to light may cause decomposition

Hazardous

Does not occur.

Polymerization:

SECTION 11 - TOXICOLOGY INFORMATION

Signs & Symptoms of

Exposure & Overexposure:

This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Possible adverse reactions are due to overdose and induced hyperthyroidism. Occupational exposure has not been fully investigated.

Medical Conditions Aggravated by

Accidental Exposure:

Individuals with cardiovascular diseases, endocrine disorders such as diabetes mellitus, adrenal insufficiency (Addison's disease), hypopituitarism, and diabetes insipidus may be aggravated by accidental exposure. Exposure may potentiate the

effects of anticoagulants and the anorectic effects of individuals taking

sympathomimetic amines.

Acute Toxicity:

Compound
Levothyroxine Sodium

<u>Type</u>	Route	<u>Species</u>	<u>Dosage</u>
$\overline{\text{TD}_{\text{LO}}}$	Oral	Woman	117 mcg/kg/60D-I
LD_{50}	IV	Rat	20 mg/kg
LD_{50}	SC	Rat	50 mg/kg
LD ₅₀	IP	Rat	20 mg/kg

Other:

NA

SECTION 12 - TRANSPORTATION INFORMATION

UN/NA Number:

NA

U.S. DOT Hazard

NA

Class:

Proper Shipping Name:

NA

Shipping Label:

NA

SECTION 13 - DISPOSAL INFORMATION

Disposal Procedure: Treatment, storage, transportation, and disposal must be in accordance with

applicable federal, state, and local regulations.

SECTION 14 - OTHER

Key to Abbreviations: ACGIH - American Conference of Governmental Industrial Hygienists

HEPA - High Efficiency Particulate Air

IARC - International Agency for Research on Cancer

NA - Not Applicable NE - Not Established NG - Not Given

NIOSH - National Institute for Occupational Safety and Health

NTP - National Toxicology Program OEL - Occupational Exposure Limit

OSHA - Occupational Safety and Health Administration

PEL - Permissible Exposure Limit

PPM - Parts Per Million QS - Quantity Sufficient

RCRA - Resource Conservation and Recovery Act

STEL - Short Term Exposure Limit TLV - Threshold Limit Value USP - United States Pharmacopeia

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Abraxis BioScience, Inc. assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.



SAFETY DATA SHEET

SECTION 1: IDENTIFICATION

Product Name: Levothyroxine Sodium for Injection

Product Use/Restriction: Hormone

Manufacturer Name: Fresenius Kabi USA, LLC Address: Three Corporate Drive Lake Zurich, Illinois 60047

General Phone Number: (847) 550-2300 (888) 386-1300 Customer Service Phone Number:

Health Issues Information: (800) 551-7176 October 12, 2011 SDS Creation Date: SDS Revision Date: June 10, 2015

(M)SDS Format:

SECTION 2: HAZARD(S) IDENTIFICATION

GHS Class: Reproductive toxicity. Effects on or via lactation.

Hazard Statements: May cause harm to breast-fed children.

Precautionary Statements: Obtain special instructions before use. Do not breathe dust/fume/gas/mist/vapours/spray.

Avoid contact during pregnancy and while nursing. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product. IF exposed or concerned: Get medical advice/attention.

Emergency Overview: This product is intended for the rapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert. Reproductive

effects.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Contact with eyes may cause irritation. Eye:

Skin: May cause skin irritation.

Inhalation: May cause irritation of respiratory tract.

Ingestion: May cause irritation.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS#	Ingredient Percent	EC Num.
Mannitol	69-65-8	3 mg/vial	
Levothyroxine Sodium	55-03-8	100 , 200, and 500 mcg/vial	
Dibasic Sodium Phosphate, Anhydrous	7558-79-4	0.5 mg/vial	

SECTION 4: FIRST AID MEASURES

Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of Eye Contact:

the eyes by separating the eyelids with fingers. Get immediate medical attention.

Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists. Skin Contact:

If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention. Inhalation:

If conscious, flush mouth out with water immediately. Call a physician or poison control center Ingestion:

immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

Levothyroxine Sodium for Injection Fresenius Kabi USA, LLC Revision: 06/10/2015

SECTION 5: FIRE FIGHTING MEASURES

Flash Point: 200

Flash Point Method: Closed cup Auto Ignition Temperature: Not established. Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established.

Fire Fighting Instructions: Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to

minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible,

contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

involving this material.

Use extinguishing measures that are appropriate to local circumstances and the surrounding

environment.

Protective Equipment: As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent)

Hazardous Combustion

Byproducts

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of combustion.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personnel Precautions: Evacuate area and keep unnecessary and unprotected personnel from entering the spill area

Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as

listed in Section 8.

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: This material will settle out of the air.

Methods for cleanup: Use an industrial vacuum cleaner with a high efficiency filter to clean up dust. Avoid dust generation.

SECTION 7: HANDLING and STORAGE

Handling: When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes.

Use with adequate ventilation. Use only in accordance with directions

Storage: Store at refrigerated temperatures 2 to 8° C (36 to 46° F). [See USP Controlled Room Temperature].

Protect from light. Retain in carton until time of use

Work Practices: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

Engineering Controls: General ventilation is sufficient if this product is being used in a controlled medical setting (clinic,

hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended

exposure limits.

Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data.

Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being

used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible

under certain circumstances. Consult the NIOSH web site (http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal

protective equipment.

EXPOSURE GUIDELINES

Revision: 06/10/2015

SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Physical State Appearance: Lyophilized powder. (May appear as a lyophilized solid or film)

Color: White

Boiling Point: Not established. Melting Point: Approximately 256 °C

Levothyroxine Sodium for Injection Fresenius Kabi USA, LLC

Page 2 of 4

Solubility: Soluble in water. Vapor Density: Not established. Vapor Pressure: Not established. Percent Volatile: Not established. Not established.

Molecular Formula: Mixture 798.86 Molecular Weight: Flash Point: 200

Flash Point Method: Closed cup Not established. Auto Ignition Temperature:

SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Hazardous Polymerization: Not reported

Conditions to Avoid: No conditions contributing to instability are known to exist for normal handling of this product.

SECTION 11: TOXICOLOGICAL INFORMATION

Mannitol:

Ingestion:

OP2060000 RTECS Number:

Oral - Rat LD50: 13500 mg/kg [Details of toxic effects not reported other than lethal dose value]
Oral - Mouse LD50: 22 gm/kg [Behavioral - Somnolence (general depressed activity); Gastrointestinal
- Ulceration or bleeding from small intestine] Ingestion:

Levothyroxine Sodium:

RTECS Number: XP3583000

Inhalation: Inhalation - Rat TCLo: 5 mg/m3/4H [Endocrine - Changes in adrenal weight Blood - Changes in other

Inhalation - Rat TCLo: 0.1 mg/m3/4H [Endocinie - Changes in adienal weight Blood - Changes in other cell count (unspecified)]

Inhalation - Rat TCLo: 0.1 mg/m3/4H [Cardiac - EKG changes not diagnostic of specified effects Liver - Other changes Biochemical - Metabolism (Intermediary) - Other]

Inhalation - Rat TCLo: 0.56 mg/m3/4H [Endocrine - Other changes Blood - changes in serum

composition (e.g. TP, bilirubin, cholesterol)]
Inhalation - Rat TCLo: 1.43 mg/m3/4H [Nutritional and Gross Metabolic - Body temperature decrease]

Oral - Mouse LD50: >10000 mg/kg [Behavioral - Somnolence (general depressed activity) Lungs, Thorax, or Respiration - Respiratory stimulation]

Subcutaneous - Rat LD50: 50 mg/kg [Details of toxic effects not reported other than lethal dose value] Intraperitoneal. - Rat LD50: 20 mg/kg [Details of toxic effects not reported other than lethal dose value] Other Toxicological Information:

Dibasic Sodium Phosphate, Anhydrous:

RTECS Number: WC4500000

Eye - Rabbit Standard Draize test.: 500 mg/24H (RTECS) Eye:

Skin: Administration onto the skin - Rabbit Standard Draize test.: 500 mg/24H [mild]

Ingestion: Oral - Rat LD50: 17000 mg/kg [Details of toxic effects not reported other than lethal dose value]

SECTION 12: ECOLOGICAL INFORMATION

No ecotoxicity data was found for the product. Ecotoxicity:

Environmental Stability: No environmental information found for this product.

SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated.

IATA Shipping Name: Non regulated. IATA UN Number: Non regulated

Levothyroxine Sodium for Injection Fresenius Kabi USA, LLC Revision: 06/10/2015

IMDG UN NUmber: Non regulated. IMDG Shipping Name: Non regulated.

SECTION 15: REGULATORY INFORMATION

Mannitol:

TSCA Inventory Status: Listed EINECS Number: 200-711-8 Canada DSL: Listed

Listed

<u>Levothyroxine Sodium</u>: TSCA Inventory Status:

Canada DSL: Listed **Dibasic Sodium Phosphate, Anhydrous:** TSCA Inventory Status: Listed EINECS Number: 231-448-7 Canada DSL: Listed

SECTION 16: ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: 1 HMIS Fire Hazard: 1 HMIS Reactivity: 1 HMIS Personal Protection: X

October 12, 2011 SDS Creation Date: SDS Revision Date: June 10, 2015 MSDS Revision Notes: Version 0

SDS Format:

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.

Levothyroxine Sodium for Injection Fresenius Kabi USA, LLC Revision: 06/10/2015 Page 4 of 4